Peritransplant pancreatitis: A marker of high mortality and graft failure in liver transplant patients

Tara A. Russell, Sarah Park, Vatche G. Agopian, Ali Zarrinpar, Douglas G. Farmer, Sean O'Neill, Islam Korayem, Samer Ebaid, Jeffrey Gornbein, Ronald W. Busuttil, Fady M. Kaldas – 14 March 2017 – Perioperative pancreatitis is a significant comorbid condition in surgical patients. However, the degree to which pancreatitis affects graft and overall survival in liver transplant recipients has not been evaluated. This study assesses the impact of pancreatitis on graft and patient survival in adult orthotopic liver transplantation (OLT).

Double‐blind randomized controlled trial of the routine perioperative use of terlipressin in adult living donor liver transplantation

Mettu Srinivas Reddy, Ilankumaran Kaliamoorthy, Akila Rajakumar, Selvakumar Malleeshwaran, Ellango Appuswamy, Sukanya Lakshmi, Joy Varghese, Mohamed Rela – 14 March 2017 – Perioperative terlipressin (Tp) during living donor liver transplantation (LDLT) has been shown to reduce intraoperative portal pressures and improve renal function. Its role and safety profile have never been evaluated in a double‐blind randomized controlled trial (RCT). The aim was to evaluate the hemodynamic effects, clinical benefits, and safety of perioperative Tp infusion in adult LDLT.

Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta‐analysis

Benjamin Menahem, Jean Lubrano, Christophe Duvoux, Andrea Mulliri, Arnaud Alves, Charlotte Costentin, Ariane Mallat, Guy Launoy, Alexis Laurent – 14 March 2017 – This meta‐analysis compared the effects of liver transplantation (LT) and liver resection (LR) on overall survival (OS) and disease‐free survival (DFS) in patients with hepatocellular carcinoma (HCC) small transplantable HCC or within Milan criteria. Articles comparing LR with LT for HCC, based on Milan criteria or small size, published up to June 2015 were selected, and a meta‐analysis was performed.

Evaluation of donor workups and exclusions in a single‐center experience of living donor liver transplantation

Adianto Nugroho, Ok‐Kyung Kim, Kwang‐Woong Lee, Sanghee Song, Hyeyoung Kim, Suk Kyun Hong, Kyung Chul Yoon, Hyo‐Sin Kim, YoungRok Choi, Hae Won Lee, Nam‐Joon Yi, Kyung‐Suk Suh – 14 March 2017 – The process of evaluating potential donors in liver transplantation is important to ensure donor safety and provide optimal recipient outcomes. However, there has been no report about donor exclusion rates and reasons for such exclusion in Korea. In this study, we aimed to elucidate the outcomes of potential living liver donor evaluation in a major living donor liver transplantation center.

Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy

Marie Sinclair, Anthony Schelleman, Daljean Sandhu, Peter W. Angus – 13 March 2017 – We report a case of dramatic systemic inflammatory symptoms and biochemical signs of inflammation related to multiple hepatic adenomas that completely resolved after cessation of the oral contraceptive pill (OCP) and associated adenoma regression. This represents a case of dramatic symptoms that resolved after estrogen withdrawal alone. (Hepatology 2017;66:989–991).

Drug rechallenge following drug‐induced liver injury

Christine M. Hunt, Julie I. Papay, Vid Stanulovic, Arie Regev – 13 March 2017 – Drug‐induced hepatocellular injury is identified internationally by alanine aminotransferase (ALT) levels equal to or exceeding 5× the upper limit of normal (ULN) appearing within 3 months of drug initiation, after alternative causes are excluded. Upon withdrawing the suspect drug, ALT generally decrease by 50% or more. With drug readministration, a positive rechallenge has recently been defined by an ALT level of 3‐5× ULN or greater.

Subscribe to